A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Second Life Therapeutics
Onchilles Pharma Inc
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Marengo Therapeutics, Inc.
Rapa Therapeutics LLC
BioAtla, Inc.
Aminex Therapeutics, Inc.
iTeos Therapeutics
Innolake Biopharm
GeneMedicine Co., Ltd.
Klus Pharma Inc.
Kineta Inc.
Incyte Corporation
Dynavax Technologies Corporation